CoChat
Sign Up
Cited by 552Extracellular vesicles in diseaseMicroRNA in disease regulationParkinson's Disease Mechanisms and Treatments

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease

Open access
Gui, YaXing, Liu, Hai, Zhang, LiShan, Lv, Wen, Hu, XingYue·2015·Oncotarget
DOI 10.18632/oncotarget.6158PMC PMC4741914
Open this paper in CoChat — free accountOpen PDF

Abstract

// YaXing Gui 1 , Hai Liu 1 , LiShan Zhang 1 , Wen Lv 1 and XingYue Hu 1 1 Department of Neurology, Sir Run Run Shaw Hospital, Affiliated with School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China Correspondence to: YaXing Gui, email: // Keywords : Parkinson’s diseases (PD), Alzheimer’s diseases (AD), cerebrospinal fluid (CSF), exosome, microRNA, Pathology Section Received : May 24, 2015 Accepted : September 30, 2015 Published : October 19, 2015 Abstract The differential diagnosis of Parkinson’s diseases (PD) is challenging, especially in the early stages of the disease. We developed a microRNA profiling strategy for exosomal miRNAs isolated from cerebrospinal fluid (CSF) in PD and AD. Sixteen exosomal miRNAs were up regulated and 11 miRNAs were under regulated significantly in PD CSF when compared with those in healthy controls (relative fold > 2, p < 0.05). MiR-1 and miR-19b-3p were validated and significantly reduced in independent samples. While miR-153, miR-409-3p, miR-10a-5p, and let-7g-3p were significantly over expressed in PD CSF exosome. Bioinformatic analysis by DIANA-mirPath demonstrated that Neurotrophin signaling, mTOR signaling, Ubiquitin mediated proteolysis, Dopaminergic synapse, and Glutamatergic synapse were the most prominent pathways enriched in quantiles with PD miRNA patterns. Messenger RNA (mRNA) transcripts [amyloid precursor protein, APP), α-synuclein (α-syn), Tau, neurofilament,light gene (NF-L), DJ-1/PARK7, Fractalkine and Neurosin] and long non-coding RNAs (RP11-462G22.1 and PCA3) were differentially expressed in CSF exosomes in PD and AD patients. These data demonstrated that CSF exosomal RNA molecules are reliable biomarkers with fair robustness in regard to specificity and sensitivity in differentiating PD from healthy and diseased (AD) controls.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6158

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. [1]Lang AE Lozano AM Parkinson's disease. First of two parts N Engl J Med 1998 339 1044 1053 9761807
  2. [3]Hachiya NS Kozuka Y Kaneko K Mechanical stress and formation of protein aggregates in neurodegenerative disorders Med Hypotheses 2008 70 1034 1037 17910993
  3. [4]van Dijk KD Teunissen CE Drukarch B Jimenez CR Groenewegen HJ Berendse HW van de Berg WD Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach Neurobiol Dis 2010 39 229 241 20451609 PMC7126274
  4. [5]Dubois B Feldman HH Jacova C Cummings JL Dekosky ST Barberger-Gateau P Delacourte A Frisoni G Fox NC Galasko D Gauthier S Hampel H Jicha GA Meguro K O'Brien J Pasquier F Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 2010 9 1118 1127 20934914
  5. [6]Waxman EA Giasson BI Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau J Neurosci 2011 31 7604 7618 21613474 PMC3122484
  6. [7]Vekrellis K Xilouri M Emmanouilidou E Rideout HJ Stefanis L Pathological roles of alpha-synuclein in neurological disorders Lancet Neurol 2011 10 1015 1025 22014436
  7. [8]Hong Z Shi M Chung KA Quinn JF Peskind ER Galasko D Jankovic J Zabetian CP Leverenz JB Baird G Montine TJ Hancock AM Hwang H Pan C Bradner J Kang UJ DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease Brain 2010 133 713 726 20157014 PMC2842513
  8. [9]Mollenhauer B Locascio JJ Schulz-Schaeffer W Sixel-Doring F Trenkwalder C Schlossmacher MG alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study Lancet Neurol 2011 10 230 240 21317042
  9. [10]Lasser C Alikhani VS Ekstrom K Eldh M Paredes PT Bossios A Sjostrand M Gabrielsson S Lotvall J Valadi H Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages J Transl Med 2011 9 9 21235781 PMC3033821
  10. [11]Valadi H Ekstrom K Bossios A Sjostrand M Lee JJ Lotvall JO Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat Cell Biol 2007 9 654 659 17486113
  11. [12]Yuan A Farber EL Rapoport AL Tejada D Deniskin R Akhmedov NB Farber DB Transfer of microRNAs by embryonic stem cell microvesicles PLoS One 2009 4 e4722 19266099 PMC2648987
  12. [13]Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 281 297 14744438
  13. [14]Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology PLoS One 2014 9 e94839 24797360 PMC4010405
  14. [15]Delay C Mandemakers W Hebert SS MicroRNAs in Alzheimer's disease Neurobiol Dis 2012 46 285 290 22285895
  15. [16]Soreq L Guffanti A Salomonis N Simchovitz A Israel Z Bergman H Soreq H Long non-coding RNA and alternative splicing modulations in Parkinson's leukocytes identified by RNA sequencing PLoS Comput Biol 2014 10 e1003517 24651478 PMC3961179
  16. [17]Cummings JL Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates J Geriatr Psychiatry Neurol 1988 1 24 36 2908099
  17. [18]Hughes TA Ross HF Musa S Bhattacherjee S Nathan RN Mindham RH Spokes EG A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease Neurology 2000 54 1596 1602 10762499
  18. [19]Schapira AH Recent developments in biomarkers in Parkinson disease Curr Opin Neurol 2013 26 395 400 23823465 PMC4196782
  19. [20]Kang JH Irwin DJ Chen-Plotkin AS Siderowf A Caspell C Coffey CS Waligorska T Taylor P Pan S Frasier M Marek K Kieburtz K Jennings D Simuni T Tanner CM Singleton A Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease JAMA Neurol 2013 70 1277 1287 23979011 PMC4034348
  20. [21]Shi M Bradner J Hancock AM Chung KA Quinn JF Peskind ER Galasko D Jankovic J Zabetian CP Kim HM Leverenz JB Montine TJ Ginghina C Kang UJ Cain KC Wang Y Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression Ann Neurol 2011 69 570 580 21400565 PMC3117674
  21. [22]Hall S Ohrfelt A Constantinescu R Andreasson U Surova Y Bostrom F Nilsson C Hakan W Decraemer H Nagga K Minthon L Londos E Vanmechelen E Holmberg B Zetterberg H Blennow K Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders Arch Neurol 2012 69 1445 1452 22925882
  22. [23]Thomas B Beal MF Parkinson's disease Hum Mol Genet 2007 16 2 R183 194 17911161
  23. [24]Hebert SS Horre K Nicolai L Papadopoulou AS Mandemakers W Silahtaroglu AN Kauppinen S Delacourte A De Strooper B Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression Proc Natl Acad Sci U S A 2008 105 6415 6420 18434550 PMC2359789
  24. [25]Junn E Lee KW Jeong BS Chan TW Im JY Mouradian MM Repression of alpha-synuclein expression and toxicity by microRNA-7 Proc Natl Acad Sci U S A 2009 106 13052 13057 19628698 PMC2722353
  25. [26]Cho HJ Liu G Jin SM Parisiadou L Xie C Yu J Sun L Ma B Ding J Vancraenenbroeck R Lobbestael E Baekelandt V Taymans JM He P Troncoso JC Shen Y MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein Hum Mol Genet 2013 22 608 620 23125283 PMC3542867
  26. [27]Booth AM Fang Y Fallon JK Yang JM Hildreth JE Gould SJ Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane J Cell Biol 2006 172 923 935 16533950 PMC2063735
  27. [28]Balaj L Lessard R Dai L Cho YJ Pomeroy SL Breakefield XO Skog J Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences Nat Commun 2011 2 180 21285958 PMC3040683
  28. [29]Sethi P Lukiw WJ Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex Neurosci Lett 2009 459 100 104 19406203
  29. [30]McKhann G Drachman D Folstein M Katzman R Price D Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 1984 34 939 944 6610841
  30. [31]Hughes AJ Daniel SE Kilford L Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 1992 55 181 184 1564476 PMC1014720
  31. [32]Tateno F Sakakibara R Kawai T Kishi M Murano T Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease Alzheimer Dis Assoc Disord 2012 26 213 216 22037599
  32. [33]Zhang Y Londos E Minthon L Wattmo C Blennow K Liu HJ Bronge L Aspelin P Wahlund LO Medial temporal lobe atrophy increases the specificity of cerebrospinal fluid biomarkers in Alzheimer disease with minor cerebrovascular changes Acta Radiol 2009 50 674 681 19455444
  33. [35]Johansson SM Admyre C Scheynius A Gabrielsson S Different types of in vitro generated human monocyte-derived dendritic cells release exosomes with distinct phenotypes Immunology 2008 123 491 499 17949417 PMC2433319
  34. [36]Anglicheau D Sharma VK Ding R Hummel A Snopkowski C Dadhania D Seshan SV Suthanthiran M MicroRNA expression profiles predictive of human renal allograft status Proc Natl Acad Sci U S A 2009 106 5330 5335 19289845 PMC2663998
  35. [37]Papadopoulos GL Alexiou P Maragkakis M Reczko M Hatzigeorgiou AG DIANA-mirPath: Integrating human and mouse microRNAs in pathways Bioinformatics 2009 25 1991 1993 19435746
  36. [38]Reczko M Maragkakis M Alexiou P Grosse I Hatzigeorgiou AG Functional microRNA targets in protein coding sequences Bioinformatics 2012 28 771 776 22285563
  37. [39]Paraskevopoulou MD Georgakilas G Kostoulas N Vlachos IS Vergoulis T Reczko M Filippidis C Dalamagas T Hatzigeorgiou AG DIANA-microT web server v5. 0: service integration into miRNA functional analysis workflows Nucleic Acids Res 2013 41 W169 173 23680784 PMC3692048
  38. [40]Hsu SD Lin FM Wu WY Liang C Huang WC Chan WL Tsai WT Chen GZ Lee CJ Chiu CM Chien CH Wu MC Huang CY Tsou AP Huang HD miRTarBase: a database curates experimentally validated microRNA-target interactions Nucleic Acids Res 2011 39 D163 169 21071411 PMC3013699

Cited by

Sorted by citations

Authors
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X.
Affiliations
  • Sir Run Run Shaw Hospital (CN)
  • Department of Neurology, Sir Run Run Shaw Hospital, Affiliated with School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
ORCID
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2015-10-19
Volume
6
Issue
35
Pages
37043-37053
ISSN
1949-2553 (ISSN-L)
DOI
10.18632/oncotarget.6158
PMC
PMC4741914
OpenAlex
W1751448311
Cited by
552
References
2
Citations by year
2026: 17 · 2025: 51 · 2024: 63 · 2023: 51 · 2022: 72 · 2021: 65 · 2020: 66 · 2019: 65 · 2018: 41 · 2017: 35 · 2016: 22 · 2015: 2
FWCI
14.48
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Oncotarget (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81401038)
  • Natural Science Foundation of Zhejiang Province
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
Parkinson's disease, Alzheimer's disease, exosomal microRNAs, miRNA expression profiling, differential diagnosis, biomarkers, miR-1, miR-19b-3p, miR-153, miR-409-3p, miR-10a-5p, neurotrophin signaling, mTOR signaling, ubiquitin-mediated proteolysis, dopaminergic synapse, glutamatergic synapses, long non-coding RNA, amyloid precursor protein, alpha-synuclein, tau protein, neurofilament light chain, fractalkine
MeSH terms
Alzheimer Disease, Diagnosis, Differential, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Parkinson Disease, Prognosis, RNA, Messenger, Biomarkers, Case-Control Studies, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, MicroRNAs, Exosomes, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review